In Vivo and in Vitro Effects of Debio-025, a non-immunosuppressive Cyclosporin A Derivative on Duchene Muscular Dystrophy | Debio 025 | /

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

In Vivo and in Vitro Effects of Debio-025, a non-immunosuppressive Cyclosporin A Derivative on Duchene Muscular Dystrophy

J. Reutenauer, O.M. Dorchies, O. Vuadens, G. Vuagniaux and U.T. Ruegg

11th International Congress on Neuromuscular Diseases - July 2006 - Istanbul/Turkey (abstract)